<SEC-DOCUMENT>0001193125-14-068418.txt : 20140226
<SEC-HEADER>0001193125-14-068418.hdr.sgml : 20140226
<ACCEPTANCE-DATETIME>20140226074536
ACCESSION NUMBER:		0001193125-14-068418
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140226
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140226
DATE AS OF CHANGE:		20140226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		14642827

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d685402d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;26, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2014, Galectin Therapeutics&nbsp;Inc. (the &#147;Company) issued the attached press release, which is being furnished and
not filed, and is attached hereto as Exhibit 99.1.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and
shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference
in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Pro Forma
Financial Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February 26, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;26, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d685402dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g685402ima1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Secures U.S. Patent for its Proprietary </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Inhibitor GR-MD-02 in Fatty Liver Disease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Norcross, Ga., February&nbsp;26, 2014</B> &#150; Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins
to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled &#147;Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic
steatohepatitis and non-alcoholic fatty liver disease.&#148; The patent covers the Company&#146;s carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing
patent protection through 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fatty liver disease, which results in severe scarring of the liver (cirrhosis), affects as many as 15&nbsp;million
Americans. There are no currently approved pharmaceutical therapies. Intervention in fatty liver disease patients with advanced fibrosis, with the intent of reversing the fibrosis, is a potentially important therapeutic approach in this unmet
medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This patent, which provides patent protection through 2031, represents a major milestone for the company in that it covers the use of
GR-MD-02 in our primary development program to treat patients with fatty liver disease with advanced fibrosis&#148;, said Dr.&nbsp;Peter&nbsp;G. Traber, CEO and CMO of Galectin Therapeutics. &#147;Patent claims also cover the use of GR-MD-02 in
combination with multiple other agents that may have potential activity in the disease that are under investigation elsewhere, including bile acids as in development by Intercept Pharmaceuticals.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The major claims are for methods of obtaining galectin inhibitor compounds, obtaining a composition for parenteral or enteral administration in an acceptable
pharmaceutical carrier and administering to a subject having at least one of the following: fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic hepatitis with liver fibrosis, non-alcoholic steatohepatitis
with cirrhosis, or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma. The use covers reversing or slowing the progression of disease activity or medical consequences of the disease. Applications are pending in multiple
countries to extend patent protection globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety,
tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease with advanced fibrosis. Last month, the Company
announced that patient enrollment in the first cohort of the Phase 1 trial was complete and results are expected to be announced around the end of the first quarter of 2014.. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g685402ima1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Fatty Liver Disease with Advanced Fibrosis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to
affect nine to 15&nbsp;million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with
fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available.
Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics
(NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging
extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization
for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current
expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that our development program for GR-MD-02 will
lead to the first therapy for the treatment of fatty liver disease with fibrosis. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that we may not be
successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of our other drugs in development. Our current clinical trial and any future clinical studies may not produce positive results in a
timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management
and regulatory agencies. Regardless of the results of any of our development programs, we may be unsuccessful in developing partnerships with other companies that would allow us to further develop and/or fund any studies or trials. To date, we have
incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations For a discussion of additional factors impacting our
business, see our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to
change, we disclaim any obligation to update forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter G. Traber, MD, 678-620-3186
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, CEO,&nbsp;&amp; CMO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@galectintherapeutics.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g685402ima1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g685402ima1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+@"]`P$1``(1`0,1`?_$`,L````&`@,!````````
M```````&!P@)"@0+`0,%`@$!``$$`P$!``````````````0!`@,%!@<("0H0
M```&`@$#`@0"!`<'%0````$"`P0%!@<("0`1$B$3,105"D$647$B%V&!D:&6
M&%CPL4(C)";8T>$R4C2T)35UE;;6-W>W.&AX&2DY$0`!`P(#!`8%!P@+`0``
M```!`!$"`P0A$@4Q(A,&05%A,A0'<8&1P4+PH;$C%18(X?%2LC.S=#718G*2
M0]-4165U-QC_V@`,`P$``A$#$0`_`)KN6OEJS+C;9W"7%-QR,ZQ/[^['/H5M
M.9`L[0D[3M9Z3-$5DC6B;A#INFTI:BUAFZF`1<IJ-H^*1!RJDNHL@D8B<MCK
M@LU2F:_%S&\LYE'D0SJX21?6S+.RV1[K+1GUY4?>>%QYC&!GH6AX\KC98W@S
M;-6AW!$2$]U=0X>0$7;GC6?./'CCZ>V)XYK)>+=1L20$G:,C\?F4K[9K_BS*
M./X-FM(6%#`]GNCRR77!V6(F+;F7BTF;QS79,R`-%X\IU07`B6KA=SYDC:3C
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M@5Z]*-(E!DJ$*9VG&SZR(,)%U&#/LP<$*(>(K@!1/V-VU-+6K.YU(Z;`'Q48
M&1?8P(!;VA<OON1N8+/EFASC7HB.AU)BG&3XO,$Q<=`(B69_4GA];5<20Z(L
M=41\@_B]/]MW[]P#]7;JD]@]*Q3#RB#)@3L4*O,%F/<;';'5*C:4V64@\JYH
MR]/T;Z?#PT!*J3K)I5_JI1>FL$5)LXF)A_9.[=.NQ"I()F$PB'[(\:YHCJV:
MG'19Y+R4P"3^@V/SLO4GX8=$\L]6U+7M4\U;>A5Y<TZR-7+5D8N1(C<8@RJ$
M#=B')Q8%.-P#1LSZX8\1R5O9NVZR!-MV*9YTDBVHV/L0UMXX3`#QD<+2`BYV
MT."'/XE67<$]TP?L(`'8.MMI5K>VM`2O;@U;@[>KVOM76WF?SQR#S-?U;3R]
MY;LM)Y?A4(I5YRG*X+;#WQ``CH9^U]BL5K>+3S,\D?'U"V7I*EIEC&CXU*+G
M!@9M1XH`E($"O8(]LT?/O7_%E3!;S-Z>)OAUL%U2HMN0E]R+:A1!<JX[VLGK
MQA-U,-HIX2>JN.6MYIC^3442C&CTH5I)"RQ+I8@D*Z02*X1/V]U+V^Y^I-$0
ME%B-Y5427_RJ;_?VA)+^B%&_ZO=9^'#J"+.2Y4-^31K]8VP,F*R3Z)224_*-
M&_93<(31UR]OR]Z^9FJ?ZO'IPX=011N?;=97D-Y?N$MGMO;^N:4LD[C+/^4Z
M^=X45C1*5GMM-I,"S8^^)Q:IP=&E_D$`)V`C</`.P>G6O5%LEBE`H=B^@=Q'
MXB/J(]Q^/P]?P^'1%\+ID614252(NDJ44U45"E.FJD?]E1-0ARG*<AR"("`@
M/</3HB;]JKK3C_4#!%*UWQ8I+GH&/U;4-:).+M7,@U:6JXV"Z+QXJLFC)N+.
M-?6)5NV`$RB5LFF4PF,`F$BC2A.3C-.UNZ.Q^G&@>*L93#/3M=A`[%;$[%35
MUAL>1^1)5X^8M<;8YIM%B%K%;Y=FO#O?FGKA^P:$^6,)`.44CJD7A5SE1S9@
M[D,Q-QQ;]8<QC3[MLS67]DUBSUKW;+-9<5WYW$FEDY&FV^IW:+96^BV,B\.H
MD107#QJ=4Z)?(`6*8"(R_<5__BKOW_W65K_Q4H'1$HW"`]0C^'OCT>/'+9HQ
M::HXX=O';M4C=LT;-X959PY<+J&*FBW123$QSF$"D*41$>B(A81Y%]@>0>>R
MG-\<F-\,/-:\17F5Q:IL_LE-7]G7LS9$KX(?F9CA;'F/(L\\_I5=.Z1*I89-
M^T1='6`&[8Y2'.!%[&F_*7)97V^S)QP[7XQ@L`[OX8@V5U:P50M3F[XESGC.
M08,I5OD#$=BDXR#G6I4(V305=Q$FW!XW(8P@HI[*X)$1SV^Y.(S"^Q>--%=<
M<:&V7WHR[`N+?$8F0LB%.HV*<=-$EUGN5<[9!49RXU"I-DD!,@S;,W<I(#XE
M23+[J1SD37MP^33=GC%AL3YBW9U^P/E77'(F3(+%-RL^GUBRJ_R%AJ<M";M:
M!FYFJ9)KJ;&\UUZ+)1`HLW,>Y4=%*D1,3K)%,1-D^Z#VXW1UZX][N\P17<:5
M_`&8V%6Q+D?+TG:YPF8T&66$IMG*U2DX\&NH1<6C*5]H+=W*NY(SA%!TJ1)L
M50/<*12<:B9.WP:X'Q"WL6I&%DZ5!ZUT]Y4'-0VC7E+3;I:(QK!?DNO&AY_#
MU:@ZV2SN"IIKNUI)9".`_<06`.XU<[.A48`DC:4P31OE*NF=N9+/ND&2>/K'
M>JF7,=X.E;9E7(:=]A,EY/LYX1SCUW3HA6XU:JP$/-U5[`WE)TFH*S@0$$RE
M\?$0ZP"WH"L;B,(BL0V8#%NI;"KJNJ5K&GIE:YKST^G+-&F9DP!9GR['`<#J
M<MM1PYE^9?9OBFE\;V`VFE)N.O&0LF5C'C#/LYG(A3B\?1X3=D:O,5PE5+88
M%W'1#-\+1=9^NW<&:B8?'N"9LR@)V-KVJY'\W557)^A^JV"38H<QRLMCN:W$
MR=>L9WG.L9[(KQTW2<<TRH2SK'U;L29?**=6M\Q=/$%$G"K-JBH4PD7/$;RF
MQ/*!BC*LI-8HD<%9[UQR>^PYL#B-[-HV1E6;HP(Z`CVO6)-JR&2@I!S&O$">
MXB15%=FJ0WF4"J'H0ZME",L2,5*7*U"O2LW`6=]%,WE@JR4LVKLFY23.XB$K
M`@W:3!6*ARC\N:0;MDTU#%_:,0/'OXF,`V\.!K^(.,\I'9BS^O!3:5]=T;:K
M:4YD6]:492'68/E/JS'UJE1R7[.6W8_9B^Q3V6D2XVQ3:YRC8[J_S"J<8S"O
M/U(B:LBS$IBHK3<_)LEA%PH!E2-1(D0Q2]^^RM:5*)SF()[=BA0$X4YPE*4\
MQP,F)C_98!O6Z/VOO$EL'LGB"E9HH]OQ=#UBXMGKJ(8S\K8FLZT^E3#V)6,X
M!A!/44%3.HTQR"FKY%*(=A[^O6&4*,2Q=U>R>GE;BKY'\XQ=+A<K[$XYNL/C
MZ!:UVJQDM9;8=FQ:-4C(`]<(I51,LG.N&X@DJ_<^Z[.F4"^8`';JSB</"GW>
MU42+CP1;7A\;_A/_`)YM8?WZMU?"N7WMBKB=BR$^"O:TC-XV'(&$O)=U'+$[
M3-K]"M$90BAC#^5_03&>E``[?`!'OUDX\>HIEE\A^507<+^,WW%?]RUD_3_*
M(&K4;?X/,N'L;24JB=FRLT):C1V4<.248JL!$7#>U0]92;(^(B"CTYD0'W`$
MG4)46R;2$!*/CZ@!A#OW$>_;T_'\.WP_@Z(JIWW+.&+3KUH_F3>O7S9_;7"^
M:X;)6,57T?4=E,HL,;2\3;[%$4B3@F..36!6L0*:2#I-TW"-1:>*Z1S'`_N'
MZ(CI]MG@^Z9;T?P'OIGS9W:_-F;,@R>5G"$9D+8+(DWBZ'@8NVV7';&*_=FM
M,FK,NK\M!G=BY?).'!72H'3$@%+T1/?N7(C4Y;;?)6C/'/ABD9QVLASDMNT&
M1W`H4'7G7Y=15*(1F,\7NM1SBS9%R0J9($$:_%)K22PD%-1VV!);VR*!KD4Q
M]FZB_<#\%#K/N=@SA>;/:Y.14^@T&#QECFBM4+F9$:[CZKL%YNP?2S**^:SJ
M9EY1^Y,F4143+_BRD4[/W%:A1X5M^NW?UQ96OP[?'*F/_7U^(?M!ZA^GHB9%
M2[9<J3]I9%VC'JC]M;HSBU<EC'<;YE?LD'=*=1LN^:F3`5`490SQPL';U[$Z
M(D-^VITAUVSIQ&8%O\U-9U:6=[<LT,+0VH.SF>L:U]*8C,H6%D`DJ6/\AURN
MQ[H\,5H=0Z;4JJX"!SF,)^B*<W%_$?HKB+96N;>UC&USD-E*HP=14-EV]9KS
M)D:U)Q3V`=556+=N[Q>9])^P&!D%6R:+@IR$(<?``'UZ(JYW#I9)&[?<Y\T,
M[DQ0Z]]AZ]?:O42R8`+N.I]9RWCRLQ32,]T3'19M:?$1A"^`^)D3`/KY=^B*
MZ?(L(R51%C*1S*3;>XU<?+/VC=ZW]]NN"S1;V')#I@LU<)@HF80[D.4!`0$`
M'HBJ]_>`"!N'B6^(B79?"'?N`^@_YW@/J(>O8>B*Q%J[V_JSZ[_#L."\2?R?
MN_KWIT15;M:Q`/O"]ZP'XCI161_7_F7K2/\`>$.B+-^\9*`Z8:<]_$2_UX:1
MW`W80$#42[@("`^@@/X]$5N2%``B8HH`4`)&1X=B@`%``:D``*````4.WIV]
M.B*H=]L04P;;\\_Z`WB2#OW]`$+YL%WZ(K:LQ?*A!VFI4B7L$='6V](V%U3H
M!XX30D;(E46K1_9/I**HE!Z>%9/D5ER$'S(D;S[>)3"!%2RY+M7[=KCL[D!^
M_BW?[NLIV>;OF/[1[*OTMX2PN59>6K:CWU03G8*1<+)&;B8IS(%(J4O@(B$R
MC7IP&\[HOO"_*#MEKUC"JXCQK.T-C1Z:U=-8-"8HK*7D"$DY1[*KD<R!G@+N
MUS/'YBD'Q$Q@$I0]>LDJ<9%SM55:%T`OFSV2,$)9-VR-#1-AN<B:5IT&SK+>
MGNH6D$012CWDZT,X,HF\GG1CN$R+%(=)`2`(`)^W4.K$1FT=B;=B;_S*;?YK
MTMUCJ&4,"R-=B[?,YBKE,?+V>OHV1B,#(P%KD72*3%==NFFY,ZC$1*IY")2@
M(?CUQCFG5;G1M,%Y:@&H:T8X]1$C[EZ0_"SY5<K></F/5Y8YN%<Z1#2J]P.%
M/ASXM.I1C#%I;K3FX;J5:='GVY'#QL@Y-;<3?,-GL.@D8,5QW@"3UO.JN/(G
MU/U$18)`'Z.P_IZZ^^_NL?HP^9?07_X4\BN/X?+JG%_B??PU80Y9^&+'G(^^
MQMG?'&0I+6;>37U]%2^#-DZO'?/+-G-=E2V"OUV^1#=1!U-P,7/?Y4Q<H*`Z
MCE%5#%!9(ZC=3N1?&E&K"&SW*YBVLQ=`V_X\S9OO4"V"+5SQI[FW#CFAY&^0
M2203LLECK,=IQ;::%)2W@95PU3,]0*L802*FGV*!$S3D?T>Y'>:7'\+KM?8S
M&O'AJ*SN$1>+@TL=F89]V.RE*U\RBE;9O8&@+L<:TBO1+IPHZ^6"?D'"KM-)
M0YQ*GX"12Y<:FDL3QV:8XAU`@\@2&48O$Q+<DUO$I"-:Z^FBVJZV"Y'%>'9O
M9!!G\FI/B@4`6.)BI`81[CT15U]`=$>5SB;W[WKLE`UDQ]NG@#<^]OKQ$Y4'
M/U3Q+8ZW))V^Z6FMO+L%IBYN?*"25V=MIALU8._<633<-E#`(IB1';D7XZN5
M/(VZ/'AR75Z-Q/LQDK5K(QG]LU.QI.16*JI2*"6>83+6(H&3<E`A*7^8F"`]
M3F)>6*S$CL6YFD>BV*<O1$Z'D8Q)RS;C<<N5]46>L^(YW*.U;24D+/-K[`5"
MM5'6>ICE9C:*?B`$C5TLEENUU^E5UHB]GD/DV3B3=K"4#(I$\B)RW%;@#9^B
MZ!TG0'>C66EU&K8QP&3!LA:ZOFJNY/K69JO)(2E>DF1Z[%1$9.5%8]6?=EA6
M563%8QO9/V[=B)D.A>JN]G!E*9?UYQK@6T;]\?M^R))9/PO,8FNM`KVQF#9B
MP%;,9FIW6A9-GZ3`7*">M(UJ87\5)>8.$CKBD'OG12(I=<52FZ6?<T4W*F2J
M')Z?:]XZB[$M'X.E;?3KMF3.]NL$?]*CY3+CRD.;!2J#CZAM'*[F/A(^5D9*
M2EC$7=+HH(%;JD46>X_%WLU@[DRKG,/QJPU/OF4;#!GI>U^JESLS2B1^<*FZ
MBF$)*SM&N;U,\-$V]Y&0S`ZB$AX(?48U!R4YA.JF<B?R[V6WPV&I\CCS&.B6
M6=2[K:HQ>N2V;MD,@X36J6'DI9N=M+W"HUS%&0<@6W*MGKZ!U%89F#:+CW#X
M$3NG**!52=$28<S_`!M9"W[XNK/I[BBYJ2>7*D7%UKQ_/Y,E3J+7ZS8J!)N9
MG<K,9,Q&TW=XPSOW'YBB0C]<IU`!,3=B+ITHSCRG2>&\-47)W'Y!X,>X-Q4G
M6\FN;YG*C2[W.=CHE)3K--J^#6=2D)=*GI7&<:-WK^<M"A&D8U3402;NE%2*
MD(HPL3:A<O6/^;'-?*W*Z2X=D:+FS%Q,..<-L-N:4A;JQ7&,!CV%B;%^:G%5
M4A969*XQRBJY;%;I(G3>&*0X&3`PD2K_`'">D_)'R;5/#V"-;-;\9,Z#A[+%
M;S6?+5^V$K$,ZMLPUI[J-/5(ZBDAP?Q#.)DIYTFL]<NS"Z!J4Z292GZ(IQJ=
MEO<1/6<UQM6G<(PV0AE(Z&1U_B=BJ4^@;$BA]*:NK(RR^O7V\+#QBB:KIP1H
MY8G>%3;@00,=0O1%`EPJ:4<I&A.U6Y=YS]J]B1SC/>_.".5;+8:-LK6921P@
MN:QY`L+D`K;JOE=Y`C4&]Z%MXMU&;HQVP'`OB<0`B(WW:NRN8-.JIQI[*X"M
M"E-ROBK:#($[69D$@<M%2.,:?)34',L3B"<G7K)$.5V4@U-V!=JN<H"4P@8"
M++U$^YJXJM_<2Q.+^02+K6N^17#5J2RUC*<%)6/"<K-I)^TI.4?(;!D^6JZ:
MPG.)"R?TYPT*;P!PJ`>8D3IOZT?VU.NID\HH;`ZBR#V+*>9B6['($KF.227;
MD%1(T'2&#ZVK&?@<G9("L_(AA[]R_'JSCOL<^W^A,%"#N']S,3>K<;3_`$[T
MBBK90M:[-M[KJSRIE>T(GA+SF6'9Y?J;H*C"U]!15Q4\;O%TDQ>%<G^H229"
MHJ)H-P.DI>"^*NAM/H]RGX^Y"_\`))CS_P!QM0_Z)WKKA7/_`/(8_P`3#]6:
M]M?@&_\`9[G_`*.Y_?VZI3-_^*)C_E&N?[SM7732^P?^[#T'Z0MK;UZ:7YH$
M.P?HZ(AT1#HB';^[]?Q_EZ(AT1<#_%Z_'JH0@$,4EUVQDPO5CI\S)S]J9,:G
M]<4-7H.?DX2(L#J99H,6[BP%BG31=^6"(D=1JD<WME66$X@)@#M<Y;L4NVU&
M=E`T*<092(Q(!;KV@[?H3#^.F!G,D:ZX1R_;\@9'E+G$W#-J$JZDKC.2C*WP
MZ>1\AU&)B;.PD'2C%\A#QS5F9D<J8*H*-2>)A[F[Z#0GK:=0KN3)I.Y?I7._
M,&I0T[F*[TVPI4(V>XS1B#'=!)!`Z2ZZ]2MA9J%AJ+CN]QMTL*.2=C=K<94S
M)$[8T9U8']#R-E"=A8"1;R+MS/%A&U1K*S)F[.<Q2J-")>V!#$-UDM;XT\\8
MQ>/B)@$GI'T>E0>8-#MJ]"=Q8SA&I3LK>I.E&.&^")2=QB^)#'`C'H2Z8RVT
MC<N*E=4;&.0Y:FR\3DR3IU]^FG;5B>5QI,C!K,Y*2?(-8VLJ7!TDL>#56<*)
M/4$#**>UV`O4BGJF;/(C"$#+V?+!:75>7:EA3-M<5Q"\GPP:>#@3!Q#$[,'<
M#:^S;BT#:V7R!B>MYB8X.MD!4KLSH\G4WEIM]%BF2T5;V4DZD96S/"2RY:NS
MJKN-*@L0Y%EGIWC;Y4BHJF*3+#4HU;6E<1;+4V=@[5FN>5(:;JM;3O$B5Q;<
M8R`B2YW&$<<7]D6+G!8,3NA'VB#USFZ7C"TSY-C[)D&EP":LW78@M;M..8^X
M2$TVL"[IT8ZT6Y/2)`K=XS(J!NR0F(7W/2'XUQ1D,>,6"SUN5A:W%]:W=P(U
M].;-@^=V&&.!<@-CCV+I;[R4V0:U2*8TNU*Y0LN2<L8E7Q@84%Y"OW+";<SK
M(A)2<BDY5BI!QK91HHT>($43>%DFWH03&`EU351;0=G^LE''H(9_9[T^YU_'
M-<7%:,+'PU*N)AN[6S9`Q(QW).'P;I=&I/:V.![!1CK%V18.5L.N]TV&:PMI
M;L*]-,&%!?P<79:-/Q4@Y*\AK2@YGT/:%0ORBI1,('\0]91U'+/++9PI3_NL
MZCQY?N)6%:^A6$[*C<TZ,IC'&J)&!'I$2_5ZE@5C:"5NV4<"U"I8Z75J6:M=
MG^P))^8GXUA-0,>#^D-HV#<0Y?>*H[(6Y)>_XJB43]@3,(%-WQT;V$JU/'"M
M$D*0.5K/3],OKBM7(KV=U&B0`X)EF[06W"QZ.U$;"FR=6;8XPQ5Z?6LDV"ZY
M9L.>&]5J>1;NUF[4W2Q)=;*WR++6K(+U=^T)#1,J"36.`AEC>RZ:-TR@0AC$
MQQKCP<#%\=CG:S]/M5FI:'5I7%W7O+B(TZWI4GJQBP)D'B!%]I&TD]!)2G&V
MDB6N5\;88F:5,U>\Y!J%>MOY>M$U78J:8LY9281EF\2V5?F:7=:CJQ`%FR1#
MITNT(\;J^T=(YCEGF[B)BG\9B"'VX_3VK!2Y>A<Z=<ZF*@,(R,7`P.78Y?=,
MGW7#'K54+[W,0'531X0'N`;!9`]?Q_[.41`>WQ]2CWZNCO;_`,L5QZ&Y2X71
MA\SCWK7%>11^(_S#_J=7(N/(@?#M_)_K=$3UN-T?_L)T9-W]!VXUX$![_``R
MQ50'^$.PCU0;5=#:?ET+:$?<ACVTCQZ/_J-J'\]2O77"^?\`^0Q_B8?JS7MO
M\`T)3\YKD0+'["N?W]NJ4C<__`TN;L/;ZG7`[]O3_<EI]/CUTTOK[P*_VL-X
M=T^[M6UPZ]-+\TJ'1$.B(=$0Z(AT1<#V_']/50J%L'ZUY$PV([BWS8LA)Q@K
MM%4BR$00BDFS$Q1#YB/(LRD$C/$_\`!05]?\$>A=\=JR1)%8%@9]1V>O\Z:9
MHU`X#@M>*TTUJNM[N>&5)RY*U.4O+6PM9-O(#<YX+<V:)VRI52?%N6Z_/B87
M+<X>]Y>V<4_#K6Z)&TIZ?".FRE.T8L9.[=.T1/S+DW.MQJEQS!.IS#0M:&JN
M,T:1B8NP9\E2I%V;XDD]!J^I+=SK^-7R-E-\NQV;V`D,3!(L;P0DSFYPID8<
MS0<S\[1&::4`P-^8P0.]^5C1#W/E'"@>SU%H4].`EPIS,>/)W=L^&88Q&'S=
MJV=Y=Z].UN83M;&$#9VXJ2@:>:-$9N%*+5I'-)QG8$X0S".#J5@*O8"3HAWF
M#+UD5?#TG(9;3J43&,K,6C5Z05LLX&0%Z>L_J"3EPR;6@'XQ@.7#UC[GN?3@
M.GV`,LX6!MZH,I"B:,W9\(?$8X>QG/4%KM6KZQXP1U:C;_:(E1<DPXA(&YF:
MI\0;/@,!',V"3AI6M1SZ^:<Q,9D'**6,F=\Q^XUEL[1E?AL4I948:RJ4AA86
MZE(573CG<*9ZFB-BCFR0*%2\5"._8,,:A3TL:?:QI5*AM0?JCO.3V[K^T!;*
MXNN9/O5JE:O;VOVS*WJBZIO#APIEN(8GBY21AW9R.U@<4@+N)Q4UG=!(K7^S
MY6DL;R6T>PKJ#LSUO+DG*_.N,=9G+<(Z,;WVO1\ZXA6%N/*&6%PP>)'*14!6
M.`DZAUXVHGI\:!F:0F<I+XX#:X'K<!;2-2ZJ0UBIK4+6&J"WB\!E(E+,Y<PF
M8NV41:0Q(,0EOJM=TT76Q'#TN^W5GD]KGO/PTBUM65M5RU)9N1;RP[&!;VLQ
M35O!-TQ,8);ZI'-XH&Y6?RXD+\H(SIPTLP(G*0'B)XXOG^(=W9UX-VK4UZ_-
M(I5YW-&B=/-I;@QD:?"%'>\.8;XQ?/E:1D[N$H65Z]KF^M-0)<[UE&&O47@3
M,7DK&L[NK9['@HS^L)96"V@%/E'#<I)@(Y1/Q*QE_=$09=R>X4)5U&RD3QI2
M!X$@6?\`9X9C@#CL[>Q8]&N=?IZ?<FPM[6>E2O*!J"9APXUAQ."(O4CMW]AD
M,`Y'3@XUK6M9)[5`,>9"R8K8H37-X3#!TF5K!Y<->U5\?E]V\?/T=-!JU:O`
M@A3!^$7("<0\BG#W@")3IZ6*EKDJ5#,1/"[V(_K;OTLL^JW7,DZ>L>.MK2-.
MI?TS=933^KKCBY(TFJEP7J9LG$&&,ATD6AU73HS/7*)Q_DO)"5M)D/8U[@*S
MI1]O/?E9<9Z;4V*B5VTQ0A;_`)%).F6(]-,,"1OS!6WRZXJ_+&&53A9BWC&,
MI\-SE.+]O1LZ\%2ZNN8B;^I<VUGX25*D*T7I\*(_PI0:KWV[N64BVT;$K-U@
MM>0O.*W^0[I?#3;.[XO1QO"W-I8_E9;)*1["2GO(!:;JA7R5G<E.\/,!&NFW
M^2D3^I$(U]L#4E"SXT3*<\[188MTM\.WKQ]*U%K5UC[/K1M:5+P9C/.08X1P
MS#O]T?"X/3E?%1P\^E1X@;;B'`#?EZRC?,7XW9Y)LR^(']&C\PR#B5NQZN5*
M<92!,0X[R'()MT8(2J$%XBV2$P=B*&'N7K:P_9[O<_/^5<957K]S'V3']K;8
M/^C>[?\`HR]$0_<Q]DQ_:VV#_HWNW_HR]$2[ZN8B^SS8[*Z^O<!;29WF,X,\
MU8Q=8=B)&O;B)1LKE!O<X56BQK]6P:Z14$FS>V4C9)4SQTV;`F81453)W.!5
MB[X*VKRG0>C,]@"LM-^[C::5A]/*,(O!R=3:WYU(+WTL-82Q3-5/'55MLV#4
M\8=Z81.W(W\BAY'`WB`\?YFIZ34TT1UJ<Z=EQ8L8YB<S28;L9%F?H;M7?GX<
MK[S:T_GFK6\FK.VON:3I]43IUY48P%N:E/B2>O7MX.)Y`-\EB6B0Y$"*6./M
MI?I[X$\_9I%D+R*%V?Z-M-W*Z*C,?3P`!PH!OVT3.O@`A^SZ]A[=^!^$\OO]
?3</Z*O\`E+VO]YOQZ>.$ON]H_B6.'$T]FP_Y/WK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
